Objectives. ABT-122 is a dual-variable-domain immunoglobulin that neutralizes both TNF-a and IL-17A. The objective of this work was to characterize exposureresponse relationships for ABT-122 relative to adalimumab (TNF-a inhibitor) using ABT-122 phase 2 trials in patients with RA or PsA.
Introduction
RA and PsA are chronic, autoimmune, inflammatory disorders that are heterogeneous in nature and have similar yet distinct clinical characteristics and overlapping yet distinct pathophysiologies [1] . Numerous proinflammatory cytokines arising from both innate and adaptive immune responses have been implicated in the pathogenesis of RA and PsA [1, 2] . Both disorders cause considerable pain and can lead to irreversible joint deformity or destruction, impaired function and decreased quality of life if left untreated [3] . In addition, patients with PsA may suffer additional disease burden caused by the disfiguring skin lesions [3] . Although previously thought to be mild and non-progressive, PsA, like RA, is now recognized as a debilitating disorder, which for almost half of patients causes irreversible joint deformity and disability within 2 years of disease onset [3] . Thus, timely diagnosis and treatment of RA and PsA to mitigate joint damage and improve functional status, with an overall goal of achieving remission or low disease activity, is key [47] .
Treatment of RA and PsA has improved considerably with the use of biologic agents that target the underlying inflammatory pathways to go beyond symptomatic improvement and modify the disease process [6, 810] . Agents targeting TNF-a (etanercept, golimumab, infliximab, adalimumab and certolizumab pegol), IL-17 (secukinumab, brodalumab and ixekizumab) and/or IL-12/23 (ustekinumab) have demonstrated efficacy in RA or PsA or both [6, 8, 1114] , in line with observations that patients with RA or PsA have increased amounts of TNF-a and IL-17-producing CD8 + T cells in synovial fluid [1517] and that IL-12 and IL-23
are key inflammatory mediators in psoriasis and PsA [18] . Dual cytokine inhibition is being explored as an innovative treatment for RA, PsA and other immune-mediated diseases [19] . ABT-122 is a dual-variable-domain (DVD) IgG1 immunoglobulin that concurrently neutralizes TNF-a and IL-17A [20] . Based on the extensive knowledge of already approved treatments targeting the TNF pathway, the recently available clinical data from agents targeting the IL-17 pathway, especially with regard to efficacy on skin lesions, and enabling pharmacokinetic and safety data from phase 1 studies [21, 22] , ABT-122 was advanced to randomized, double-blind, active-controlled phase 2 trials in RA and PsA. The efficacy and safety results from these phase 2 studies have been previously presented [23, 24] . Results from the trials demonstrated dose-and time-dependent improvements in efficacy measures during 12 weeks of treatment with ABT-122; however, the improvements in the joint responses measured by 20%, 50% and 70% improvement in ACR response criteria (ACR20, ACR50 and ACR70, respectively) and skin responses measured by 50%, 70% and 90% improvement in Psoriasis Area and Severity Index (PASI) response criteria (PASI50, PASI75 and PASI90, respectively) were not broadly different from those of adalimumab, but with occasionally higher numerical responses with the upper doses of ABT-122 relative to adalimumab [23, 24] .
The aim of the analyses described in this report was to characterize the exposureresponse relationships between ABT-122 or adalimumab serum concentrations and the joint responses, ACR20, ACR50 and ACR70, in patients with RA or PsA and the skin responses, PASI50, PASI75 and PASI90, in patients with PsA to evaluate if these relationships are different between ABT-122, which neutralizes both TNF-a and IL-17A, and adalimumab, which neutralizes only TNF-a. Given the differences in the pharmacokinetics between ABT-122 and adalimumab [25] , comparison of efficacy by evaluating the dose-response relationship only can be misleading. The exposureresponse analyses for ABT-122 relative to adalimumab were particularly important in this case because they normalize for exposure differences and the shape of these relationships can provide insights into any potential benefit of dual inhibition of TNF-a and IL-17A vs inhibition of TNF-a alone.
Methods
Study designs, participants, pharmacokinetic sample collection and efficacy measurements
The studies were conducted in accordance with good clinical practice guidelines and the ethical principles that have their origin in the Declaration of Helsinki. The protocols and informed consent forms were approved by the institutional review boards and participants provided written informed consent before any study-related procedures were performed.
Two studies [one in RA patients (NCT02433340) and one in PsA patients (NCT02349451)] were included in the analyses. The studies were phase 2, randomized, double-blind, double-dummy, active-controlled, placebo-controlled (PsA study only), parallel-group, multicentre studies in patients aged 18 years or older who had an RA or PsA diagnosis of at least 3 months' duration and who had an inadequate response to MTX [23, 24] . In the RA study, patients were assigned in equal numbers to receive ABT-122 (AbbVie Inc., North Chicago, IL, USA) 60 or 120 mg every other week (EOW) or 120 mg every week (EW) or adalimumab (AbbVie Inc., North Chicago) 40 mg EOW. In the PsA study, patients were assigned in a 3: 3: 3: 1 ratio to receive ABT-122 120 or 240 mg EW, adalimumab 40 mg EOW, or placebo. In both studies, treatments were administered subcutaneously for 12 weeks. Patients continued to take their weekly stable dose of MTX and folate throughout the study.
Patients visited the study sites weekly beginning with the baseline visit on day 1 (week 0). Blood samples for determination of serum drug concentrations and assessment of antidrug antibody response were collected before dosing on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71 and 78, and again on days 85 and 127 (6-week follow-up visit) in the RA study and days 1, 15, 29, 43, 57 and 71, and again on days 85 (week 12) and 148 (70-day follow-up visit) in the PsA study. Serum concentrations of ABT-122 and adalimumab and ADAs against ABT-122 and adalimumab were determined using validated assays at AbbVie (Ludwigshafen, Germany) as previously described [22, 26] .
The assessments of ACR20, ACR50 and ACR70 in patients with RA or PsA were captured at weeks 2, 4, 8 and 12 in both the RA and PsA trials and also captured at week 6 in the RA trial. The PASI50, PASI75 and PASI90 in patients with PsA were determined at weeks 4, 8 and 12 in those with psoriasis involvement 53% of body surface area, as previously described [23, 24] . A summary of ACR20, ACR50 and ACR70 responses from the phase 2 studies in patients with RA or PsA and the PASI50, PASI75 and PASI90 responses from the PsA study is shown in Supplementary Table S1, available at Rheumatology online [23, 24] .
Exposureresponse analyses
Serum concentration data for ABT-122 and adalimumab were analysed using a non-linear mixed-effects modelling approach in NONMEM version 7.3 (ICON Development Solutions, Hanover, MD, USA). The details of the pharmacokinetic analyses for ABT-122 have been previously described [25] . Similar methodology but with a one compartment pharmacokinetic model was used for the analysis of adalimumab serum concentration data. These pharmacokinetic models were used to provide the full time course of ABT-122 and adalimumab serum concentrations over 12 weeks that were used as the exposure input for the exposureresponse analyses for ACR and PASI responses.
The relationships between the ABT-122 and adalimumab serum concentrations and time course of ACR20, ACR50 and ACR70 responses (patients with RA or PsA), PASI50, PASI75 and PASI90 responses (patients with PsA), and patient dropouts were characterized using a Markov modelling approach ( Fig. 1 ), similar to that described by Lacroix et al. [27] . In the models, active therapy (i.e. ABT-122 or adalimumab) was assumed to enhance the transition of the status of patients to higher levels of response (e.g. no response to ACR20, ACR20 to ACR50 and ACR50 to ACR70, or no response to PASI50, PASI50 to PASI75 and PASI75 to PASI90). The models also allowed for transitions from each response state to dropout.
The assessment of predictive performance of the exposureresponse analyses was done by performing stochastic simulations [28, 29] , as described in the Supplementary Data, Methods section, available at Rheumatology online. The relationships between ACR or PASI responses at week 12 and ABT-122 or adalimumab average serum concentration (C avg ) were also evaluated graphically. Plots were generated to display both the observed and the model-based exposureresponse relationships. For the observed exposureresponse relationship, observed ACR and PASI response data across all dose levels of ABT-122 were combined and patients were ordered from lower to higher C avg values (i.e. classification by exposure instead of dose). Patients were divided into four groups based on quartiles of C avg , such that each group represented 25% of patients. The percentage of patients achieving ACR and PASI responses in each of the four groups was calculated and plotted against the median C avg in each of the four groups. Similarly, data for adalimumab were also evaluated based on four quartiles of adalimumab C avg values . For the model-based exposureresponse relationships, the ACR or PASI responses at week 12 from 1000 simulated clinical trials were summarized as medians and 90% prediction intervals (as noted above) and plotted against the C avg values.
Results

Participants
The exposureresponse analyses included serum concentration and efficacy data from a total of 221 patients in the RA study (55 each received ABT-122 60 mg EOW, 120 mg EOW, or 120 mg EW and 56 received adalimumab 40 mg EOW) and 240 patients in the PsA study (71 received ABT-122 120 mg EW, 73 received ABT-122 240 mg EW, 72 received adalimumab 40 mg EOW and 24 received placebo). The patients had mean age in the range of 48 to 58 years and had received an RA or PsA diagnosis within previous 78 years (Table 1 and [23, 24] ).
ABT-122 and adalimumab pharmacokinetics
The results of the pharmacokinetics analysis of ABT-122 have been previously described [25] . ABT-122 mean steady-state observed serum concentrations (C trough ) at week 12 were 1.4, 4.4 and 12.1 mg/mL in the 60 mg EOW, 120 mg EOW and 120 mg EW treatment groups, respectively, in patients with RA and 11.6 and 27.3 mg/mL in the 120 mg EW and 240 mg EW treatment groups, respectively, in patients with PsA. Based on the pharmacokinetic analysis, ABT-122 steady-state C avg values over the dosing interval were 15, 34 and 60 nM for the 60 mg EOW, 120 mg EOW and 120 mg EW doses, respectively, in patients with RA and 52 and 105 nM for the 120 mg EW and 240 mg EOW doses, respectively, in patients with PsA. The adalimumab steady-state C avg values were 30 and 26 nM in patients with RA or PsA, respectively. Hence, on a molar serum concentration basis, ABT-122 C avg values at steady state were approximately one-half, comparable, 2-fold and 4-fold higher than adalimumab 40 mg EOW at ABT-122 doses of 60 mg EOW, 120 mg EOW, 120 mg EW and 240 mg EW, respectively.
Exposureresponse analyses
ACR scores in RA and PsA
The time courses of the observed and exposureresponse model-predicted ACR20, ACR50 and ACR70 responses for placebo, different doses of ABT-122 and adalimumab are shown in the plots in Supplementary Fig. S1, available at Rheumatology online. The percentages of ABT-122, adalimumab and placebo patients with ACR20, ACR50 and ACR70 responses over 12 weeks of treatment were well described by the Markov model, as demonstrated by consistency of the observed ACR responses with the 90% prediction intervals ( Supplementary Fig. S1 , available at Rheumatology online). In the RA study, the serum concentrations associated with half-maximal effects (EC 50 ) on the transition rates to progressively higher ACR responses (e.g. no response to ACR20, ACR20 to ACR50 or ACR50 to ACR70) were 2.6 nM [relative standard error (RSE) 130%] for ABT-122 and 7.2 nM (RSE 126%) for adalimumab. In the PsA study, the EC 50 values were 6.5 nM (RSE 170%) for ABT-122 and 13.2 nM (RSE 61%) for adalimumab. Figures 2 and 3 show the observed and modelpredicted relationships between ABT-122 or adalimumab C avg values in patients with RA or PsA and the ACR20, ACR50 and ACR70 responses at week 12. The observed exposureresponse relationships for ACR responses are shown by solid symbols, which represent observed ACR responses in each of the four quartiles of C avg values across all doses within each study (i.e. classification by exposure instead of doses).
As shown in Fig. 2 , the observed and exposureresponse model-predicted ABT-122 ACR 20, ACR50 and ACR70 responses at week 12 were at the plateau at the exposures (C avg ) associated with the 120 mg EOW dose (mean C avg of 34 nM) in the RA study. Similarly the ACR responses were already at the plateau at the exposures associated with the lowest ABT-122 dose of 120 mg EW in the PsA study (Fig. 3) . It is noteworthy that the shape of the exposureresponse relationship was similar for ABT-122 and adalimumab; moreover, the ACR responses for ABT-122 were comparable to those observed for the adalimumab 40 mg EOW dose at similar molar exposures, which is more readily apparent in the RA study, in which a significant overlap was observed between ABT-122 and adalimumab exposures. In the PSA study, the highest quartile of adalimumab exposures, which starts to overlap with ABT-122 molar exposures in this study, achieves efficacy similar to the plateau of ABT-122 ACR responses.
PASI scores in PsA. The time courses of the observed and exposureresponse model-predicted PASI50, PASI75 and PASI90 responses in PsA patients for placebo, different doses of ABT-122 and adalimumab are shown in Supplementary Fig. S2 , available at Rheumatology online. Similar to ACR responses, the time courses of PASI responses were also well described by the Markov model ( Supplementary Fig. S2 , available at Rheumatology online). The wider prediction intervals for placebo resulted from the lower precision in estimating the placebo effect due to the small placebo sample size enrolled in this study. The EC 50 values for the transition rates to progressively higher PASI responses (e.g. no response to PASI20, PASI20 to PASI50 or PASI50 to PASI70) were 27 nM (RSE 91%) for ABT-122 and 34 nM (RSE 58%) for adalimumab. Similar to the trends observed for ACR responses, the observed and exposureresponse model-predicted ABT-122 PASI50, PASI75 and PASI90 responses at week 12 were at a plateau at exposures associated with the 120 mg EW dose, the lowest dose evaluated in the PsA study (Fig. 4) . Moreover, the observed and model-predicted PASI responses for the higher two quartiles of adalimumab C avg (patients with C avg above the median values) were comparable to the plateau of the PASI responses for ABT-122 (Fig. 4) .
Discussion
ABT-122, a DVD IgG1 immunoglobulin that concurrently neutralizes TNF-a and IL-17A, has been evaluated for safety and efficacy in dose-ranging phase 2 studies in patients with RA or PsA. Despite the overall conclusion that ABT-122 efficacy was not clearly and consistently differentiated from adalimumab in these two trials [23, 24] , there were some numerical efficacy differences favouring ABT-122 relative to adalimumab, particularly for the highest ABT-122 dose of 240 mg EW in the PsA trial (Supplementary Table S1 , available at Rheumatology online). The relative contribution of IL-17A inhibition to ABT-122 efficacy and the strength of the evidence leading to termination of ABT-122 clinical development remained a question of clinical interest. Characterizing the exposureresponse relationships for ABT-122 relative to adalimumab was key in understanding the potential efficacy benefit of dual inhibition of TNF-a and IL-17A by ABT-122 vs inhibition of TNF-a alone by adalimumab. The pharmacokinetics of ABT-122 [25] and adalimumab were characterized with population analyses using serum concentration data from the present trials along with ABT-122 phase 1 results. These analyses indicated that the apparent clearance with subcutaneous administration was 3-fold faster for ABT-122 relative to adalimumab. Consequently, relative to adalimumab 40 mg EOW steady-state molar C avg , ABT-122 steady-state molar C avg values were approximately one-half, comparable, 2-fold and 4-fold higher at ABT-122 doses of 60 mg EOW, 120 mg EOW, 120 mg EW and 240 mg EW, respectively. The present analyses accounted for the pharmacokinetic differences between ABT-122 and adalimumab by using the steady-state average serum concentrations over a dosing interval as the measure of exposure instead of the dose, thereby allowing a less-confounded interpretation of the relative efficacy of the two agents.
The use of continuous-time (longitudinal) Markov modelling [27] for the exposureresponse analyses provides several advantages in analyses of ordinal, categorical response data. Firstly, the successive ACR or PASI responses assessed repeatedly over time for each individual are not independent. For instance, a patient who achieves an ACR20 response at week 6 following initiation of a treatment is likely to have an ACR20 response at a later time point and also may have a higher likelihood of achieving an ACR50 response than a patient who was an ACR20 nonresponder. The Markov approach addresses this correlation and dependence between successive observations (Fig. 1) . Secondly, as described previously [27] , this approach allows for simultaneous analyses of ACR and PASI response data along with any dropouts. The simultaneous analysis of different levels of ordinal response data allows for a more robust estimate of efficacy across all levels of response. Thirdly, integrated analysis of response over the full time course results in a robust estimate of the exposureresponse relationship as it uses the complete information gathered in the course of the trial rather than just a particular time point (e.g. week 12 primary time point). This further minimizes the undue influence of an outlying or discordant response at one time point.
The results of the current analyses (Figs 24] demonstrate that the plateau of the exposureresponse relationships for ABT-122 on both joint and skin responses was achieved within the dose range evaluated in these studies, with a plateau of the ACR response observed at ABT-122 exposures associated with the 120 mg EOW dose in patients with RA (Fig. 2) . In patients with PsA, the joint and skin responses were at the plateau of exposureresponse relationship at the lowest evaluated dose of 120 mg EW (Figs 3 and 4) . While limited by evaluating one dose level only for adalimumab as a control, there was no evidence that the shape of the observed or the model-estimated exposureresponse relationships for efficacy in patients with RA or PSA was different for ABT-122 compared with adalimumab (Figs 24] . At similar molar serum exposures, ABT-122 and adalimumab efficacy was essentially the same and the plateau of ABT-122 response was not any higher than the efficacy achieved with adalimumab in patients with exposures falling within the highest adalimumab exposure quartiles (Figs 24] . These data suggest that the numerically higher responses with the highest dose of ABT-122 in PsA were driven by higher exposure of the anti-TNF component of the DVD and that the two lower exposure quartiles of adalimumab were causing the overall response of the 40 mg EOW adalimumab dose to be numerically lower than ABT-122 higher doses. Overall, the lack of clear difference in the shape of the exposureresponse relationships for ABT-122 and adalimumab suggests that dual inhibition of TNF-a and IL-17A by ABT-122 did not provide any significant advantage compared with TNF-a inhibition alone by adalimumab.
One of the limitations of these analyses is lack of anti-IL-17 control arms in the evaluated trials. Such data could have helped build additional mathematical models of the efficacy interaction between the two mechanisms. Nevertheless, the current analyses estimated the total effect for ABT-122, which was not better than adalimumab alone at comparable molar exposures. Given that TNF inhibition is believed to be more efficacious than IL-17 inhibition on the joint responses, at least in RA, the ABT-122 vs adalimumab comparison was the most relevant comparison clinically for RA and PsA. Another limitation of these analyses is use of adalimumab efficacy data at only one dose level, which provides a limited range of adalimumab exposures compared with ABT-122. However, the fact that ABT-122 efficacy vs exposure actually plateaued at exposures comparable to the adalimumab upper exposure quartiles alleviated the need for studying higher doses of adalimumab. Evaluating lower doses of both ABT-122 and adalimumab could have increased the precision of the EC 50 estimates for both agents; however, this limitation did not have a practical implication for the purpose of the studies, which was to characterize the maximal efficacy of ABT-122 and to determine whether this maximal efficacy was differentiated from adalimumab. Another limitation of the evaluated trials is the fixed ratio of the IL-17 and the TNF-a binding sites, which is inherent with the DVD immunoglobulin design. However, given the high exposures of ABT-122 evaluated and the comparability of its molar exposures and affinity to previously evaluated efficacious anti-IL-17 agents [30, 31] , such limitation should not impact the interpretation of the results from the present analyses.
The multiple-dose phase 1 study of ABT-122 was conducted in subjects with RA [22] ; however, that study was designed to primarily assess the safety, tolerability and pharmacokinetics. The very small number of subjects who were evaluated at each dose level in that phase 1 study, the limited disease activity for subjects who were enrolled, and the lack of adalimumab active comparator precluded conducting a meaningful analysis for efficacy in order to draw valid conclusions prior to phase 2 testing .   FIG. 4 Relationships between ABT-122 or adalimumab serum concentrations and week 12 PASI responses in the PsA study Solid symbols (brown and blue) represent the observed percentage of patients achieving PASI50, PASI75 and PASI90 responses in each exposure (C avg ) quartile. Dotted lines and shaded areas represent the model-based median predictions and 95% prediction intervals (PI) (2.5th and 97.5th percentiles). Black circles and lines represent the median and range of ABT-122 C avg values in a dosing interval for 95% of the patients (2.5th and 97.5th percentiles) at each dose level. C avg : average serum concentration; EW: every week.
In conclusion, exposureresponse analyses characterized the entire time course of the joint responses (ACR20, ACR50 and ACR70) and skin responses (PASI50, PASI75 and PASI90) in patients with RA or PsA following treatment with ABT-122 or adalimumab in phase 2 clinical trials. These analyses demonstrated a maximum clinical benefit (plateau of efficacy responses) at ABT-122 exposures associated with the 120 mg EOW dose in patients with RA and at the lowest dose of 120 mg EW in patients with PsA. Furthermore, the shape of the exposureresponse relationships for ABT-122 and adalimumab was not distinguishably different, with similar efficacy at comparable molar exposure ranges, indicating no clear evidence that inhibition of the IL-17 pathway provided incremental benefit in the presence of TNF-a inhibition. Based on the results from these analyses and the lack of evidence of a clinical benefit from the second mechanism contributed by the DVD relative to adalimumab alone, further clinical development of ABT-122 for the treatment of RA or PsA was discontinued.
